title: Identification of novel anti-inflammatory probiotic strains isolated from pulque.
abstract: Probiotics are live microorganisms which when administered in adequate amounts, confer health benefits on the host. Their use is more and more widespread for both prevention and treatment of diseases, including traveler’s diarrhea and inflammatory bowel diseases (IBDs). In this work, we isolated and characterized novel candidate probiotic strains from pulque (xaxtle), a traditional Mexican alcoholic fermented beverage. A total of 14 strains were obtained from xaxtle samples isolated from three different Mexican regions. Species identification was performed by biochemical methods and 16S rRNA gene targeted PCR. The isolates belonged to the Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus brevis, and Lactobacillus composti phylogenetic groups, with L. brevis being the most dominant group. Bacteria were tested for lysozyme, low pH, and bile acid resistance. Moreover, the strains were tested for adherence to human intestinal epithelial cells and screened for their immunomodulatory properties using a cellular model. Selected bacterial strains with anti-inflammatory properties were then tested in vivo in a dinitro-benzene sulfonic acid (DNBS)-induced chronic colitis mouse model, and weight loss, gut permeability, and cytokine profiles were measured as readouts of inflammation. One of the selected strains, Lactobacillus sanfranciscensis LBH1068, improved mice health as observed by a reduction of weight loss, significant decreases in gut permeability, and cytokine modulation. Altogether, our results highlighted the potential of lactobacilli isolated from pulque and in particular the strain L. sanfranciscensis LBH1068 as a novel probiotic to treat IBD.
authors.forename: Edgar
authors.initials: E
authors.lastname: Torres-Maravilla
authors.forename: Marion
authors.initials: M
authors.lastname: Lenoir
authors.forename: Lino
authors.initials: L
authors.lastname: Mayorga-Reyes
authors.forename: Thibault
authors.initials: T
authors.lastname: Allain
authors.forename: Harry
authors.initials: H
authors.lastname: Sokol
authors.forename: Philippe
authors.initials: P
authors.lastname: Langella
authors.forename: María E
authors.initials: ME
authors.lastname: Sánchez-Pardo
authors.forename: Luis G
authors.initials: LG
authors.lastname: Bermúdez-Humarán
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use*; D001422:Bacterial Adhesion; D001628:Beverages / Q000382:microbiology*; D002460:Cell Line; D016000:Cluster Analysis; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D004139:Dinitrofluorobenzene / Q000031:analogs & derivatives / Q000633:toxicity; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000382:microbiology; D006801:Humans; D007778:Lactobacillus / Q000145:classification* / Q000302:isolation & purification* / Q000502:physiology; D008800:Mexico; D051379:Mice; D008969:Molecular Sequence Data; D010802:Phylogeny; D019936:Probiotics / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use*; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S; C045305:2,4-dinitrofluorobenzene sulfonic acid; D004139:Dinitrofluorobenzene